Becton Dickinson and Co (BDX) Holdings Cut by Advisors Asset Management Inc.

Advisors Asset Management Inc. lowered its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 9.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 34,627 shares of the medical instruments supplier’s stock after selling 3,579 shares during the quarter. Advisors Asset Management Inc.’s holdings in Becton Dickinson and were worth $8,295,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Ascension Asset Management LLC lifted its position in shares of Becton Dickinson and by 4.2% in the second quarter. Ascension Asset Management LLC now owns 4,970 shares of the medical instruments supplier’s stock valued at $1,191,000 after acquiring an additional 200 shares in the last quarter. Bfsg LLC lifted its position in shares of Becton Dickinson and by 1.9% in the second quarter. Bfsg LLC now owns 10,515 shares of the medical instruments supplier’s stock valued at $2,519,000 after acquiring an additional 201 shares in the last quarter. Toth Financial Advisory Corp lifted its position in shares of Becton Dickinson and by 0.8% in the second quarter. Toth Financial Advisory Corp now owns 24,989 shares of the medical instruments supplier’s stock valued at $5,986,000 after acquiring an additional 203 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Becton Dickinson and by 0.4% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 50,849 shares of the medical instruments supplier’s stock valued at $12,181,000 after purchasing an additional 204 shares during the last quarter. Finally, Chesapeake Wealth Management increased its holdings in shares of Becton Dickinson and by 5.5% in the second quarter. Chesapeake Wealth Management now owns 4,179 shares of the medical instruments supplier’s stock valued at $1,001,000 after purchasing an additional 219 shares during the last quarter. Institutional investors own 92.39% of the company’s stock.

NYSE:BDX opened at $238.09 on Friday. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95. The company has a market capitalization of $65.55 billion, a P/E ratio of 25.11, a P/E/G ratio of 1.46 and a beta of 1.11. Becton Dickinson and Co has a one year low of $203.99 and a one year high of $265.87.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.86 by $0.05. The company had revenue of $4.28 billion during the quarter, compared to analysts’ expectations of $4.25 billion. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The firm’s quarterly revenue was up 41.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.46 earnings per share. As a group, equities research analysts anticipate that Becton Dickinson and Co will post 11.01 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 28th. Shareholders of record on Friday, September 7th were paid a dividend of $0.75 per share. The ex-dividend date was Thursday, September 6th. This represents a $3.00 annualized dividend and a yield of 1.26%. Becton Dickinson and’s dividend payout ratio (DPR) is 31.65%.

BDX has been the subject of several recent research reports. ValuEngine raised Becton Dickinson and from a “hold” rating to a “buy” rating in a report on Tuesday, June 26th. KeyCorp reaffirmed a “buy” rating and issued a $264.00 price target on shares of Becton Dickinson and in a report on Friday, August 3rd. Royal Bank of Canada reaffirmed a “hold” rating and issued a $248.00 price target on shares of Becton Dickinson and in a report on Friday, August 3rd. Citigroup increased their price target on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Finally, Wells Fargo & Co increased their price target on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Five equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $255.40.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Read More: Fundamental Analysis

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply